Profile Picture
  • All
  • Search
  • Images
  • Videos
  • Maps
  • News
  • Copilot
  • More
    • Shopping
    • Flights
    • Travel
  • Notebook
  • Top stories
  • Sports
  • U.S.
  • Local
  • World
  • Science
  • Technology
  • Entertainment
  • Business
  • More
    Politics
Order byBest matchMost fresh
  • Any time
    • Past hour
    • Past 24 hours
    • Past 7 days
    • Past 30 days

Cipla, Eli Lilly and type 2 diabetes

Digest more
Stocktwits on MSN · 2d
Cipla Shares Fall To Biggest Intra-day Lows In Six Months Despite Eli Lilly Deal For Diabetes Drug
Cipla-Eli Lilly partner to distribute Tirzepatide under the Yurpeak brand in India ・Tirzepatide is used to manage type 2 diabetes and chronic weight issues in adults ・The stock has outperformed the broader pharma index YTD Shares of Cipla fell 3.

Continue reading

 · 3d · on MSN
Eli Lilly gives Cipla license to sell weight-loss drug Tirzepatide in India
Medical Dialogues · 2d
Eli Lilly's Diabetes Drug Mounjaro Gets Second Brand Yurpeak via Cipla Deal
4don MSN

3 Things Investors Need to Know Ahead of Eli Lilly's Q3 Earnings Report

On Oct. 30, Eli Lilly will announce third-quarter earnings results that could lift the stock, or pressure it further. Here ...
The Pharma Letter
1d

Cipla and Eli Lilly partner to launch tirzepatide as Yurpeak in India

Indian drugmaker Cipla Limited has entered into a strategic marketing and distribution agreement with US pharma major Eli ...
2d

Newsbreak Confirmed: What to make of Cipla's Yurpeak pact with Eli Lilly? Nuvama raises target by Rs 74

Eli Lilly's launch of Mounjaro in India in March 2025 was the first step of Tirzepatide in the country. In June 2025, the ...
8h

Eli Lilly: Is Another Monster Quarter Coming

October 30th is the day when Eli Lilly will report its third-quarter results, including sales of its 'superstars' Zepbound ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results
Feedback
  • Privacy
  • Terms